Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

184 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients.
Tiribelli M, Bonifacio M, Binotto G, Iurlo A, Cibien F, Maino E, Guella A, Festini G, Minotto C, De Biasi E, De Marchi F, Scaffidi L, Frison L, Bucelli C, Medeot M, Calistri E, Sancetta R, Stulle M, Orofino N, Krampera M, Gherlinzoni F, Semenzato G, Pizzolo G, Ambrosetti A, Fanin R. Tiribelli M, et al. Among authors: ambrosetti a. Oncotarget. 2018 Feb 12;9(18):14219-14227. doi: 10.18632/oncotarget.24478. eCollection 2018 Mar 6. Oncotarget. 2018. PMID: 29581839 Free PMC article.
Combination of EUTOS score and 3-month BCR-ABL transcript level identifies a group of good-risk chronic myeloid leukemia patients with favorable response to frontline imatinib therapy.
Tiribelli M, Binotto G, Calistri E, Maino E, Scaffidi L, Medeot M, Nabergoj M, Ambrosetti A, Semenzato G, Fanin R, Bonifacio M; Gruppo Triveneto LMC. Tiribelli M, et al. Among authors: ambrosetti a. Am J Hematol. 2015 Jul;90(7):E135-7. doi: 10.1002/ajh.24022. Epub 2015 May 28. Am J Hematol. 2015. PMID: 25808917 Free article. No abstract available.
Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response.
Bonifacio M, Binotto G, Maino E, Calistri E, Marin L, Scaffidi L, Frison L, De Marchi F, Krampera M, Semenzato G, Fanin R, Ambrosetti A, Tiribelli M; Gruppo Triveneto LMC. Bonifacio M, et al. Among authors: ambrosetti a. Haematologica. 2015 Aug;100(8):e299-301. doi: 10.3324/haematol.2015.124685. Epub 2015 Mar 27. Haematologica. 2015. PMID: 25820333 Free PMC article. No abstract available.
Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice.
Zaja F, Mian M, Volpetti S, Visco C, Sissa C, Nichele I, Castelli M, Ambrosetti A, Puglisi S, Fanin R, Cortelazzo S, Pizzolo G, Trentin L, Rodeghiero F, Paolini R, Vivaldi P, Sancetta R, Isola M, Semenzato G. Zaja F, et al. Among authors: ambrosetti a. Am J Hematol. 2013 Nov;88(11):955-60. doi: 10.1002/ajh.23546. Epub 2013 Sep 9. Am J Hematol. 2013. PMID: 23861234 Free article.
Epstein-Barr virus DNA load in chronic lymphocytic leukemia is an independent predictor of clinical course and survival.
Visco C, Falisi E, Young KH, Pascarella M, Perbellini O, Carli G, Novella E, Rossi D, Giaretta I, Cavallini C, Scupoli MT, De Rossi A, D'Amore ES, Rassu M, Gaidano G, Pizzolo G, Ambrosetti A, Rodeghiero F. Visco C, et al. Among authors: ambrosetti a. Oncotarget. 2015 Jul 30;6(21):18653-63. doi: 10.18632/oncotarget.4418. Oncotarget. 2015. PMID: 26087198 Free PMC article.
184 results